Metropolis Healthcare

CLOSING BELL: The broader markets, meanwhile, bled more with the BSE SmallCap index sliding nearly 3 per cent, and the BSE MidCap index falling close to 2 per cent

Stocks to Watch Today: Sugar and FMCG stocks likely to be in focus as govt limits sugar exports and exempts customs duty on agri cess. Apollo Hospitals, Bata, Coal India and Nalco to report results.

Metropolis runs more than 3,000 diagnostics centers as well as pathology laboratories in India and Africa

The company is planning to add around 40 more Hitech centres during the current financial year

In Q4FY22, the company expects better profitability on account of higher QoQ volumes from large government contract and benefits of investments in digitization and marketing.

Metropolis Healthcare on Friday said its net profit declined 29.69 per cent to Rs 41.2 crore for the third quarter ended December 31, 2021. The diagnostics chain had reported a net profit of Rs 58.6 core in the same period of previous fiscal. Revenues, however, increased to Rs 293.1 crore in the period under review as against Rs 274.7 crore in the same period of 2020-21 fiscal, Metropolis Healthcare said in a statement. "We have been able to grow our non-COVID revenue despite a sharp drop in volumes from a government contract. We have made increased investments in digital and marketing, manpower & customer experience initiatives in order to strengthen our brand. This has impacted margins which we believe is a short-term phenomenon," Metropolis Healthcare Promoter and Managing Director Ameera Shah noted. The company has been able to successfully complete the acquisition of Hitech Diagnostics during the third quarter which will enable it to scale up business, improve the B2C revenue

It is assuring to see that the annual Budget has majorly focused on women, youth, and rural development

Metropolis Healthcare said its board approved the acquisition of Hitech Diagnostic Centre and its arm Centralab Healthcare Services in a combination of cash and equity shares deal.

In a Q&A, Ameera Shah says, however, that the impact of the second wave on her industry segment wasn't as bad as the first

The company's Q4 reported Ebitda margins expanded by 820 bps YoY at 33.2 per cent on the back of increased scale of business, strong cost optimization and automation efforts

According to the Union Health Ministry data, India recorded 1,03,558 coronavirus infections on Sunday, pushing the nationwide Covid tally to 1.25 crore

Metropolis will acquire 100 per cent equity of Dr Ganesan's Hitech Diagnostic Centre in a cash and stock deal

Metropolis Healthcare said it will acquire Dr Ganesan's Hitech Diagnostic Centre

Diagnostic chain Metropolis Healthcare said it will acquire Dr Ganesan's Hitech Diagnostic Centre Pvt Ltd in a cash and stock combination deal, to strengthen its leadership position in southern India

Sequent Scientific and Everyday Industries saw percentage shareholding pledged by promoters go down by over 44 per cent each and their shares rally by 68 per cent and 75 per cent, respectively

A new all time high shows bullish sentiment is here to stay in these stocks.

Thyrocare Technologies, Metropolis Healthcare and Dr. Lal PathLabs, hitting their respective record highs, were up 9 per cent to 17 per cent on the BSE in intra-day trade.

Ameera Shah, promoter and managing Director of Metropolis Healthcare, says private labs have been at the forefront of medical testing.

Today, a total of 31 companies including Voltas, Jubilant Life Sciences, and Metropolis Healthcare, are scheduled to announce their March quarter results

According to media reports, private equity giant Carlyle was looking to sell stake in Metropolis Healthcare